Stocklytics Platform
Asset logo for symbol VERA
Vera Therapeutics
VERA37
$36.62arrow_drop_down0.59%-$0.22
Asset logo for symbol VERA
VERA37

$36.62

arrow_drop_down0.59%

Performance History

Chart placeholder
Key Stats
Open$37.67
Prev. Close$36.84
EPS-2.01
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range36.19
37.96
52 Week Range9.24
50.78
Ratios
Revenue-
EBITDA Margin %-
EPS-2.01

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Asset logo for symbol LLY
Eli Lilly & Co
LLY74
Price$805.15
Perf. (24h)
arrow_drop_down1.95%-$16.03
Market Cap$738.87B
Asset logo for symbol UNH
UnitedHealth Group
UNH71
Price$570.00
Perf. (24h)
arrow_drop_up1.84%$10.32
Market Cap$527.83B
Asset logo for symbol JNJ
Johnson & Johnson
JNJ62
Price$160.66
Perf. (24h)
arrow_drop_up0.63%$1.02
Market Cap$382.01B
Asset logo for symbol ABBV
AbbVie
ABBV62
Price$185.19
Perf. (24h)
arrow_drop_up1.65%$3.02
Market Cap$326.96B

About Vera Therapeutics (VERA)

Vera Therapeutics, Inc. (VERA) is a biopharmaceutical company focused on developing novel therapies for the treatment of serious immunological and renal diseases. The company's lead product candidate, VERA-101, is a potent small molecule inhibitor of a protein called pSTAT3, which plays a key role in the immune system and is highly expressed in certain disease states. VERA-101 has shown promising results in preclinical studies and is currently being evaluated in a phase 1 clinical trial. The company believes that targeting pSTAT3 has the potential to address unmet medical needs in a range of therapeutic areas.
In recent news, Vera Therapeutics announced positive interim data from its ongoing phase 1 study of VERA-101. The data showed that VERA-101 was well-tolerated and demonstrated dose-dependent inhibition of pSTAT3 in patients with advanced solid tumors. These results validate the company's approach and support further development of VERA-101 as a potential treatment for a variety of cancers. The company plans to advance VERA-101 into phase 2 trials in the near future.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Marshall Fordyce M.D.
Headquarters
Brisbane
Employees
49
Exchange
NASDAQ
add Vera Therapeutics to watchlist

Keep an eye on Vera Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Vera Therapeutics's (VERA) price per share?
The current price per share for Vera Therapeutics (VERA) is $36.62. The stock has seen a price change of -$0.22 recently, indicating a -0.6% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Vera Therapeutics (VERA)?
For Vera Therapeutics (VERA), the 52-week high is $50.78, which is 38.67% from the current price. The 52-week low is $9.24, the current price is 296.32% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Vera Therapeutics (VERA) a growth stock?
Vera Therapeutics (VERA) has shown an average price growth of 0.41% over the past three years. It has received a score of 97 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Vera Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Vera Therapeutics (VERA) stock price performance year to date (YTD)?
As of the latest data, Vera Therapeutics (VERA) has a year-to-date price change of 134.59%. Over the past month, the stock has experienced a price change of 8.6%. Over the last three months, the change has been -7.64%. Over the past six months, the figure is 21.34%.
help
Is Vera Therapeutics (VERA) a profitable company?
Vera Therapeutics (VERA) has a net income of -$95.99M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $1.86M. Operating income is noted at -$102.01M. Furthermore, the EBITDA is $0.
help
What is the market capitalization of Vera Therapeutics (VERA)?
Vera Therapeutics (VERA) has a market capitalization of $2.02B. The average daily trading volume is 629.68K, indicating the stock's liquidity and investor engagement.

News

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
VERA THERAPEUTICS
INDUCEMENT AWARDS
STOCK OPTIONS
RESTRICTED STOCK UNITS
NEW EMPLOYEES
7/5/2024

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
DIRECTORS AND OFFICERS
6/11/2024

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHANGES IN COMPANY'S OWN SHARES
6/7/2024

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
CALENDAR OF EVENTS
CONFERENCE CALLS/ WEBCASTS
6/7/2024

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market
SECTOR ETFS
NEWS
EQUITIES
MACRO ECONOMIC EVENTS
MARKET SUMMARY
MACRO NOTIFICATION
POLITICS
TREASURIES
TOP STORIES
ECONOMICS
MARKETS
ETFS
5/31/2024

Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
HEALTH
REGULATORY INFORMATION
5/28/2024

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level